MINT1526A + bevacizumab

MINT1526A + bevacizumab is a combination therapy of two monoclonal antibodies: **MINT1526A**, a fully humanized IgG1 antibody targeting integrin alpha-5 beta-1 (α5β1, ITGA5/B1), and **bevacizumab**, a monoclonal antibody against vascular endothelial growth factor (VEGF). MINT1526A blocks the binding of α5β1 integrin to its ligands (such as fibronectin), thereby inhibiting endothelial cell functions critical for angiogenesis, including adhesion, migration, and sprouting. Bevacizumab inhibits VEGF-mediated angiogenesis. This combination is being investigated for synergistic anti-angiogenic and antitumor effects, particularly in advanced solid tumors. In a phase I clinical trial, the combination was well-tolerated and showed preliminary evidence of efficacy, but efficacy attributable to the combination could not be differentiated from bevacizumab monotherapy in that study. The main developer is Genentech. The primary clinical indication studied is advanced solid tumors, including hepatocellular carcinoma and thymic carcinoma[1][3][5][6].

Other names

RG-7594 + bevacizumab